Hiroyuki Sonoda
Technik-/Wissenschafts-/F&E-Leiter bei JCR PHARMACEUTICALS CO., LTD.
Ursprung des Netzwerks ersten Grades von Hiroyuki Sonoda
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 30 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Hiroyuki Sonoda
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| SUMITOMO PHARMA CO., LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
Nomura Securities Co., Ltd.
 Nomura Securities Co., Ltd. Investment Banks/BrokersFinance Nomura Securities Co., Ltd. (NSC) is a wholly-owned brokerage subsidiary of Nomura Holdings, Inc. (TSE: 8604; NYSE: NMR). Headquartered in Tokyo, the firm was founded in 1925. NSC places a strong emphasis on research, both fundamental and quantitative. In addition to stock and bond underwriting, their activities include IPO and M&A advisory, wealth management, separately managed accounts, fund wrap services, prime brokerage and structured equity finance. Their clients include institutions, hedge funds, private banks and private equity funds as well as corporate clients and retail investors. | Investment Banks/Brokers | Analyst-Equity | |
GlaxoSmithKline KK
 GlaxoSmithKline KK Household/Personal CareConsumer Non-Durables GlaxoSmithKline KK researches, develops, imports, manufactures and sells toiletry products. The company was founded on August 18, 1928 and is headquartered in Tokyo, Japan | Household/Personal Care | Chairman President Director/Board Member Comptroller/Controller/Auditor Director/Board Member | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Hospital/Nursing Management | Chief Executive Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
| SUMITOMO CHEMICAL CO., LTD. | Chemicals: Specialty | Corporate Officer/Principal | |
| KAWASAKI KISEN KAISHA, LTD. | Marine Shipping | Director/Board Member | |
| TOTETSU KOGYO CO., LTD. | Engineering & Construction | Director/Board Member | |
| University of Freiburg | College/University | Doctorate Degree | |
| Hautes Etudes Commerciales | College/University | Masters Business Admin | |
Barclays Securities Japan Ltd.
 Barclays Securities Japan Ltd. Investment Banks/BrokersFinance Part of Barclays PLC, Barclays Securities Japan Ltd. is a brokerage company based in Tokyo, Japan. Barclays Securities Japan provides brokerage services. The Japanese company was founded in 1987. Kentaro Kiso has been the CEO of the company since 2014. | Investment Banks/Brokers | Analyst-Equity | |
FUJIFILM Toyama Chemical Co. Ltd.
 FUJIFILM Toyama Chemical Co. Ltd. Pharmaceuticals: OtherHealth Technology Part of FUJIFILM Holdings Corp., FUJIFILM Toyama Chemical Co. Ltd. brings innovative solutions to various industries such as healthcare, graphic systems, and digital imaging. The company is based in Tokyo, Japan. The Japanese company's core technologies include chemical, mechanical, optical, electronic, and imaging technologies. With revenues of $21 billion in 2020, the company is committed to responsible environmental stewardship and good corporate citizenship. The company was founded in 1968, and the CEO is Misao Tsuda. FUJIFILM Toyama Chemical Co. was acquired by FUJIFILM Holdings Corp. from Daiichi Sankyo Co., Ltd. on October 01, 2006. | Pharmaceuticals: Other | Director/Board Member | |
| MUTUAL CORPORATION | Industrial Machinery | Director/Board Member | |
| MEDIPAL HOLDINGS CORPORATION | Medical Distributors | Chief Administrative Officer | |
| CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member | |
| Universität Stuttgart | College/University | Graduate Degree | |
| École des Hautes Études Commerciales de Paris | College/University | Graduate Degree | |
AstraZeneca UK Ltd.
 AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Future Brain KK
 Future Brain KK Investment Banks/BrokersFinance Future Brain KK is a Japanese company that engages in securities dealing and real estate management business. The company is based in Tokyo, Japan. | Investment Banks/Brokers | President | |
AstraZeneca KK
 AstraZeneca KK Pharmaceuticals: MajorHealth Technology AstraZeneca KK develops, manufactures and sells prescription drugs. It also conducts medical research. The company was founded on April 11, 1975 and is headquartered in Osaka, Japan. | Pharmaceuticals: Major | Chairman | |
| AISEI PHARMACY CO LTD | Drugstore Chains | Director/Board Member | |
Mediceo Corp.
 Mediceo Corp. Medical DistributorsDistribution Services Part of Medipal Holdings Corp., Mediceo Corp. is a Japanese company that wholesales drugs and medical devices. The company is based in Tokyo, Japan and was founded in 2004. | Medical Distributors | Director/Board Member | |
Astrazeneca Intermediate Holdings Ltd.
 Astrazeneca Intermediate Holdings Ltd. Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca Intermediate Holdings Ltd. operates as a British intermediate holding company through its subsidiaries and researches, manufactures, and markets pharmaceuticals. The company is based in Cambridge, UK. | Pharmaceuticals: Major | Director/Board Member | |
| Université Paris Nanterre | College/University | Undergraduate Degree | |
| REZOLUTE, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Hebei Jie Xi Bio-Products Co. Ltd. | Chairman | ||
MEDIE Co., Ltd.
 MEDIE Co., Ltd. Internet Software/ServicesTechnology Services Part of Medipal Holdings Corp., MEDIE Co., Ltd. is a Japanese company that provides medical information through the internet and develops and distributes computer software and medical equipment and tools. The company is based in Tokyo, Japan. MEDIE Co. was acquired by Medipal Holdings Corp. on June 01, 2013 for $8.05 million. | Internet Software/Services | Director/Board Member | |
Acerta Pharma BV
 Acerta Pharma BV Pharmaceuticals: GenericHealth Technology Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands. | Pharmaceuticals: Generic | Director/Board Member | |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France. | Financial Conglomerates | Corporate Officer/Principal | |
Japan Vaccine Co., Ltd.
 Japan Vaccine Co., Ltd. BiotechnologyHealth Technology Japan Vaccine Co., Ltd. develops and markets preventive vaccines. The joint venture company is based in Tokyo, Japan. | Biotechnology | President | |
Orchard Therapeutics (Europe) Ltd.
 Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
JCR International SA
 JCR International SA Pharmaceuticals: MajorHealth Technology Part of JCR Pharmaceuticals Co., Ltd., JCR International SA is a Swiss pharmaceutical company that manufactures pharmaceutical products. The company is based in Fribourg, Switzerland. | Pharmaceuticals: Major | President | |
| SPLine Corp. | Director/Board Member | ||
| NOILE-IMMUNE BIOTECH INC. | Pharmaceuticals: Major | Director/Board Member | |
4BIO Ventures Management Ltd.
 4BIO Ventures Management Ltd. Investment ManagersFinance 4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
| JCR USA, Inc. | Director/Board Member Chief Executive Officer | ||
| Graduate School of Innovation & Technology Management | College/University | Corporate Officer/Principal | |
| ORCHARD THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
| Pancreas Research Foundation of Japan | Chairman | ||
Luca Science, Inc.
 Luca Science, Inc. BiotechnologyHealth Technology Luca Science, Inc. is a Japanese preclinical stage biopharmaceutical company that specializes in mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Luca Science is based in Chuo-ku, JP, and was founded in December 2018 by Masashi Suganuma. The company uses its platform technology to manufacture, store, and deliver innovative mitochondrial drugs to research and develop therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. The CEO is Rick C. Tsai. | Biotechnology | Director/Board Member | |
| Alexion Pharmaceuticals, Inc. /New/ | Chief Executive Officer |
Statistik
International
| Japan | 23 |
| Vereinigtes Königreich | 8 |
| Frankreich | 7 |
| Vereinigte Staaten | 6 |
| Deutschland | 3 |
Sektoral
| Health Technology | 18 |
| Consumer Services | 8 |
| Finance | 7 |
| Distribution Services | 3 |
| Consumer Non-Durables | 2 |
Operativ
| Director/Board Member | 50 |
| Corporate Officer/Principal | 23 |
| Independent Dir/Board Member | 12 |
| President | 7 |
| Chairman | 6 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Hiroyuki Sonoda
- Unternehmensverbindungen
